TG Therapeutics completed enrollment in its phase III study of subcutaneous Briumvi for adults with RMS, keeping the program on track for a late-2026 or early-2027 data readout. The update is a modest positive for the pipeline and supports the company’s development timeline, but it is not an immediate commercial catalyst.
TG Therapeutics completed enrollment in its phase III study of subcutaneous Briumvi for adults with RMS, keeping the program on track for a late-2026 or early-2027 data readout. The update is a modest positive for the pipeline and supports the company’s development timeline, but it is not an immediate commercial catalyst.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
mildly positive
Sentiment Score
0.25
Ticker Sentiment
